1 t could be wrought by a terrorist's use of a biological agent.
2 ions and high costs restrict prescription of biological agents.
3 tribution against a robust database of known biological agents.
4 e enough to be compatible with sophisticated biological agents.
5 tifying and managing casualties from various biological agents.
6 ombining anti-VEGF therapy with cytotoxic or biological agents.
7 n ideal target for site-specific delivery of biological agents.
8 orally active small molecule alternatives to biological agents.
9 es limits the therapeutic potential of these biological agents.
10 hn's disease, there are few clinical data on biological agents.
11 are not appreciably degraded by a variety of biological agents.
12 ession of these changes could be produced by biological agents.
13 signaling pathways with small molecules and biological agents.
14 d supplementation, herbal products and other biological agents, acupuncture, massage, exercise, and p
15 re cystectomy and consolidation therapy with biological agents after first-line therapy provide a fra
16 The development of neutralising biological agents against TNF-alpha has allowed us to te
17 In parallel with the development of several 'biological' agents, alternative therapeutic options have
18 Dependent on the biological agent and contaminated food, such an outbreak
19 New therapeutic approaches, such as biological agents and mycophenolate mofetil, will also b
20 Disease-modifying biological agents and other drug regimens have substanti
21 New biological agents and somatostatin-tagged radionuclides
22 nitor the location and transfer of hazardous biological agents and to insure that any use of such age
23 omise include intravenous immunoglobulin and biological agents and trials of the newest treatments ar
24 -2 in vivo for use in combination with other biological agents, and for studies of its antitumor acti
25 es have yet to be undertaken for these novel biological agents, and it is unclear whether any of thes
26 options have expanded with the advent of the biological agents, and these may yet improve outcomes, p
27 As newer biological agents are translated from the lab to the bed
28 Biological agents are used when arthritis is uncontrolle
29 In particular, the use of biological agents as radiosensitizers has led to the inv
30 The modern development of biological agents as weapons has paralleled advances in
31 Concern regarding the use of biological agents--bacteria, viruses, or toxins--as tool
32 oday are complacent about the possibility of biological agents being intentionally used to cause wide
33 2004) for articles relating to bioterrorism, biological agents, biological warfare, hospital prepared
34 idually targeted therapies such as the newer biological agents, but how successful this approach will
35 n be protected against potentially hazardous biological agents by using engineering controls, good la
36 ention has been paid to scenarios in which a biological agent capable of person-to-person transmissio
37 All biological agents currently used for reducing TNFalpha a
38 able instruments for environmental analysis, biological agent detection, or diagnostics.
39 nostics, environmental testing and defensive biological agent detection.
40 ination procedures, the role of chemical and biological agent detectors, and potential environmental
41 Biological agents directed against the interleukin-13 pa
42 een reported in humans treated with anti-TNF biological agents, disparate rates of disease have been
43 The significant threat posed by biological agents (e.g. anthrax, tetanus, botulinum, and
44 ulin E and tumour necrosis factor alpha with biological agents, emphasise the need for careful phenot
45 cacy of a combination of methotrexate with a biological agent, especially a tumor-necrosis-factor blo
46 ur necrosis factor inhibitors were the first biological agents, followed by abatacept, rituximab, and
47 in the process of developing or acquiring a biological agent for use as a weapon.
48 Weaponization of biological agents for aerosol dispersal is difficult and
49 ocesses have led to the development of novel biological agents for the treatment of chronic inflammat
50 The development of biological agents for the treatment of solid tumours is
51 Introduction of biological agents for the treatment of the chronic infla
52 form of therapy for many patients, an era of biological agents for therapy in inflammatory bowel dise
53 Accidental release of biological agents from a bioweapon facility may contamin
54 The release of biological agents from conventional porous scaffolds is
55 For more than a decade, a biological agent has been suspected to cause free-branch
56 Deliberate contamination of food with biological agents has already been perpetrated in the US
57 Biological agents have been used as instruments of warfa
58 Biological agents have dramatically improved treatment o
59 he site of exposure, diseases resulting from biological agents have incubation periods of days.
60 The integration of these new biological agents in combination with chemotherapy, in o
61 Viruses are the most common biological agents in the sea, typically numbering ten bi
62 The role of biological agents in the treatment of this common, yet c
63 MSCs may serve as a platform for delivery of biological agents in tumors.
64 body temperatures in vitro but are effective biological agents in vivo.
65 of intensity modulated radiation therapy and biological agents into CRT treatment approaches may redu
66 ell cancer, particularly the introduction of biological agents into treatment paradigms, and some of
67 products (SMNPs) in the discovery of active biological agents is discussed.
68 care and with technological breakthroughs in biological agents, is giving new hope to the problem of
69 Published work suggests that biological agents, like traditional treatments, have the
70 ed mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites.
71 invisible, silent, odorless, and tasteless, biological agents may be used as an ultimate weapon-easy
72 der the importance of two neutrophil-derived biological agents: neutrophil extracellular traps and ec
73 molecular biology and the emergence of novel biological agents now offer the possibility of improved
74 Biological agents offer good control of rheumatoid arthr
75 olled by a magnetic field to deliver various biological agents on demand.
76 Immunotherapy with biological agents or small molecules is revolutionising
77 However, the incremental benefit of these biological agents over less expensive standard wound car
78 its of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone
79 Among 9 RCTs evaluating biological agents, several trials reported benefits with
80 ctor-beta-directed therapies and other novel biological agents such as hyperimmune caprine serum are
81 Further trials are needed for biological agents such as infliximab, rituximab and intr
82 ved to be less specific than perturbation by biological agents, such as antibody and small inference
83 Finally, we show that biological agents, such as oxidized 1-palmitoyl-2-arachi
84 Recent advances in the use of biological agents, such as rituximab, have also allowed
85 Clinical investigations of novel drugs and biological agents targeting mechanisms involving CD4 typ
86 ed studies confirm that the long-term use of biological agents targeting TNF-alpha in therapy for rhe
87 Biological agents that block key T-cell costimulatory si
88 Biological agents that block T-cell costimulatory pathwa
89 t of rheumatoid arthritis with the advent of biological agents, the mechanisms that drive cytokine pr
90 and the external environment and chemical or biological agents therein is the olfactory epithelium (O
91 potential inhibitors of the binding of such biological agents to cell membranes has increased.
92 e useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bac
93 few efforts in defining a role for the newer biological agents useful in rheumatoid arthritis and oth
94 0 bombs and 25 ballistic missiles laden with biological agents were deployed by the time Operation De
95 motherapy, oral agents, and newer injectable biological agents, which have revolutionised the managem
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。